Home > Boards > US Listed > Biotechs > Vascular Biogenics Ltd. (VBLT)

Next step is ovarian . They must succeed.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Oren1976 Member Profile
 
Followed By 2
Posts 382
Boards Moderated 0
Alias Born 12/04/16
160x600 placeholder
VBL Therapeutics' stock up on late-stage VB-111 ovarian cancer study results Seeking Alpha - 3/4/2021 8:33:16 AM
VBL Therapeutics Announces Peer-reviewed Publication of Positive Results of Pre-specified Interim Analysis of OVAL, a Phase 3... GlobeNewswire Inc. - 3/4/2021 7:00:00 AM
VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Re... GlobeNewswire Inc. - 3/1/2021 7:00:00 AM
VET, TCOM, TTM and ZI among premarket gainers Seeking Alpha - 2/23/2021 8:18:53 AM
VBL Therapeutics gets green light for VB-111 study in ovarian cancer, shares up 16% Seeking Alpha - 2/22/2021 7:32:38 AM
VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Ena... GlobeNewswire Inc. - 2/22/2021 7:00:00 AM
VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients GlobeNewswire Inc. - 1/27/2021 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/15/2021 7:05:09 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/15/2021 7:03:58 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 1/11/2021 6:02:46 AM
Securities Registration (foreign Private Issuer) (f-3) Edgar (US Regulatory) - 12/30/2020 4:17:39 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/24/2020 4:51:30 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 11/16/2020 7:18:35 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/16/2020 7:03:18 AM
VBL Therapeutics to Report Third Quarter 2020 Financial Results on November 16 GlobeNewswire Inc. - 11/2/2020 7:00:10 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/29/2020 9:01:19 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/19/2020 4:10:50 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/13/2020 8:31:06 AM
VBL Therapeutics to Provide an Update on the OVAL Study Today at the H. C. Wainwright 22nd Annual Global Investment Conferenc... GlobeNewswire Inc. - 9/15/2020 8:00:10 AM
VBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple ... GlobeNewswire Inc. - 9/11/2020 8:00:10 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/26/2020 5:21:36 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/13/2020 7:01:01 AM
VBL Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 8/13/2020 7:00:10 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/12/2020 8:46:07 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 8/5/2020 4:33:05 PM
Oren1976   Thursday, 11/15/18 08:32:35 AM
Re: MF82 post# 1969
Post # of 2015 
Next step is ovarian . They must succeed. Fever is the key. Unfortunately they don't push to fever like injecting directly to tumor and they still reduce fever using anti fever drugs. The only hope is the good ph2 result in ovarian

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences